ERBB2 and metastatic neoplasm: In the analyzed period, EMA issued 16 new indications concerning metastatic disease, of which 10 in hormone receptor-positive/HER2 negative, three in HER2-positive, one in triple-negative, and two in breast cancer with BRCA mutation.